

Altria's Modified Risk Tobacco Product Application for Copenhagen Fine Cut Snuff

Michael Fisher, PhD

Altria Client Services, Regulatory Affairs

May 2, 2019




Harm Reduction Opportunities



Range of Potentially Lower Risk Products



Note: Third party trademarks are the property of their respective owners and are included for informational purposes only.




 <u>More than 90%</u> in FDA's PATH survey say that smokeless tobacco products are just <u>as harmful</u> or <u>more harmful</u> than cigarettes

Proposed Modified Risk Claim




Lung Cancer Mortality Risks




FDA & TPSAC Conclusions on Health Risk

- FDA: "Based on the evidence described above, the proposed modified risk claim "IF YOU SMOKE, CONSIDER THIS: Switching completely to this product from cigarettes reduces risk of lung cancer" appears to be scientifically accurate." – FDA Briefing Document, p. 21
- TPSAC: DISCUSS the available scientific evidence and VOTE on the whether the proposed modified risk claim is scientifically accurate (yes/no/abstain).



Estimated Population Impact of Proposed Modified Risk Claim




FDA Conclusion on Population Health Benefit

• FDA: "Computational modeling estimated a relatively small net population health benefit from market authorization of Copenhagen Snuff Fine Cut with the proposed modified risk claim." FDA TPSAC presentation slide 49.

Changing E-vapor Use Patterns

12MM, By Usage - Total, in millions



*LA+, P30D Source: ATCT

Numbers may not foot due to rounding. 'N' represents weighted counts